Related Experiment Videos
Epidermal growth factor receptor expression: is it the same in normal and malignant endometria?
R Zarcone1, P Bellini, G Cardone
1Department of Obstetrics and Gynecology, Second University of Naples.
Clinical and Experimental Obstetrics & Gynecology
|January 1, 1995
Summary
Epidermal growth factor receptor (EGFR) was present in all normal uterine tissues and most endometrial cancers. Its absence in some cancers suggests a potential role in tumor development.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Epidermal growth factor (EGF) plays a role in cell growth and differentiation.
- Dysregulation of EGF signaling is implicated in various cancers, including endometrial adenocarcinoma.
- Understanding EGFR expression patterns is crucial for cancer research.
Purpose of the Study:
- To investigate and compare the expression of epidermal growth factor receptor (EGFR) in normal and malignant endometrial tissues.
- To determine if EGFR expression levels correlate with clinicopathological features of endometrial cancer.
Main Methods:
- Immunohistochemical techniques were utilized to detect EGFR.
- Murine monoclonal antibody 528 was employed for EGFR detection.
- The study included 39 patients: 12 with normal endometria and 27 with endometrial adenocarcinomas.
Main Results:
- EGFR was detected in all normal uterine tissues examined.
- EGFR was present in 27 out of 27 endometrial adenocarcinomas.
- EGFR was notably absent in 11 patients diagnosed with endometrial cancer.
- No significant correlation was observed between EGFR staining intensity and histologic grade, depth of myometrial invasion, or clinical stage.
Conclusions:
- EGFR is ubiquitously expressed in normal endometrial tissue.
- EGFR expression is common in endometrial adenocarcinomas, but its absence in a subset of cases warrants further investigation.
- EGFR expression levels in this study did not correlate with established prognostic factors in endometrial cancer.